Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 02 - 24 symbols : Gnmsf save search
Seagen and Genmab Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
Published: 2022-02-24 (Crawled : 17:00) - biospace.com/
GNMSF | $281.02 210
|
Health Technology
|
| O: -0.93%
H: 5.16%
C: 5.16%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: -1.6%
H: 7.46%
C: 7.28%
GMAB | $28.6 0.25% 77K
|
Health Technology
|
| O: -2.63%
H: 0.0%
C: 0.0%
tivdak cel head and neck cell carcinoma
Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
Published: 2022-02-24 (Crawled : 15:30) - globenewswire.com
GNMSF | $281.02 210
|
Health Technology
|
| O: -0.93%
H: 5.16%
C: 5.16%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: -1.6%
H: 7.46%
C: 7.28%
GMAB | $28.6 0.25% 77K
|
Health Technology
|
| O: -2.63%
H: 0.0%
C: 0.0%
tivdak cel head and neck cell carcinoma
Notice to Convene the Annual General Meeting of Genmab A/S
Published: 2022-02-24 (Crawled : 12:00) - biospace.com/
GNMSF | $281.02 210
|
Health Technology
|
| O: -0.93%
H: 5.16%
C: 5.16%
GMAB | $28.6 0.25% 77K
|
Health Technology
|
| O: -2.63%
H: 0.0%
C: 0.0%
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
AGBA | $1.05 162.5% 100M
|
Finance
INVO | $1.36 78.95% 3.6M
|
Health Technology
BPTH | $5.62 73.46% 75M
|
Health Technology
TIRX | $0.8231 69.78% 54M
|
ISPC | $0.307 44.13% 3.6M
|
Professional, Scientific, and T...
SINT | $0.0519 39.14% 350M
|
Health Technology
XPON | $2.63 36.27% 8.4M
|
ALRN | $5.53 30.12% 250K
|
Health Technology
VTNR S | $1.26 28.68% 9.1M
|
Industrial Services
HOLO | $2.86 27.68% 28M
|
Your saved searches
Save your searches and get alerts when important news are released.